Modulators of androgen synthesis
The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.
1. A method of treating an individual with a pancreatic cancer, the method comprising the step of administering to the individual a therapeutically effective amount of risperidone and about 0.01 mg/kg/day to about 0.5 mg/kg/day of 9Z,11E conjugated Linoleic Acid, wherein administration reduces a symptom associated with the pancreatic cancer, thereby treating the individual, wherein there is a synergistic effect between the risperidone and 9Z,11E conjugated Linoleic Acid.
2. The method according to claim 1 , the therapeutically effective amount of risperidone is from about 0.1 mg/day to about 20 mg/day.
3. The method according to claim 2 , wherein the therapeutically effective amount of risperidone is from about 0.5 mg/day to about 17.5 mg/day.
4. The method according to claim 1 , wherein the therapeutically effective amount of risperidone is from about 0.01 mg/kg/day to about 0.5 mg/kg/day.
5. The method according to claim 1 , wherein 9Z,11E conjugated Linoleic Acid is in an amount from about 1 mg/day to about 20 mg/day.
6. The method according to claim 5 , wherein 9Z,11E conjugated Linoleic Acid is in an amount from 0.5 mg/day to about 17.5 mg/day.
7. The method according to claim 1 , wherein risperidone and 9Z,11E conjugated Linoleic Acid are administered sequentially or simultaneously.
8. The method according to claim 1 , wherein risperidone and 9Z,11E conjugated Linoleic Acid are administered to the individual as a single composition.
9. The method according to claim 1 , wherein the reduced symptom includes a reduction in the frequency of a symptom of a pancreatic cancer, a reduction in the number of symptoms of a pancreatic cancer, or any combination thereof.
10. A method of treating an individual with a pancreatic cancer, the method comprising the step of administering to the individual about 0.01 mg/kg/day to about 0.5 mg/kg/day of risperidone and about 0.01 mg/kg/day to about 0.5 mg/kg/day of 9Z,11E conjugated Linoleic Acid, wherein administration reduces a symptom associated with the pancreatic cancer, thereby treating the individual,
wherein there is a synergistic effect between risperidone and the 9Z,11E conjugated Linoleic Acid.
11. The method according to claim 10 , wherein risperidone and 9Z,11E conjugated Linoleic Acid are administered sequentially or simultaneously.
12. The method according to claim 10 , wherein risperidone and 9Z,11E conjugated Linoleic Acid are administered to the individual as a single composition.
13. A method of treating an individual with a pancreatic cancer, the method comprising the step of administering to the individual about 0.1 mg/day to about 20 mg/day of risperidone and about OA mg/day to about 20 mg/day of 9Z,11E conjugated Linoleic Acid, wherein administration reduces a symptom associated with the pancreatic cancer, thereby treating the individual,
wherein there is a synergistic effect between risperidone and the 9Z,11E conjugated Linoleic Acid.
14. The method according to claim 13 , wherein risperidone is in an amount from about 0.5 mg/day to about 17.5 mg/day.
15. The method according to claim 13 , wherein 9Z,11E conjugated Linoleic Acid is in an amount from about 0.5 mg/day to about 17.5 mg/day.
16. The method according to claim 13 , wherein risperidone and 9Z,11E conjugated Linoleic Acid are administered sequentially or simultaneously.
17. The method according to claim 13 , wherein risperidone and 9Z,11E conjugated Linoleic Acid are administered to the individual as a single composition.
18. A method of treating an individual with a pancreatic cancer, the method comprising the step of administering to the individual a therapeutically effective amount of risperidone and about 0.1 mg/day to about 20 mg/day of 9Z,11E conjugated Linoleic Acid, wherein administration reduces a symptom associated with the pancreatic cancer, thereby treating the individual,
wherein there is a synergistic effect between risperidone and 9Z,11E conjugated Linoleic Acid.
19. The method according to claim 18 , wherein the therapeutically effective amount of risperidone is an amount from about 0.1 mg/day to about 20 mg/day.
20. The method according to claim 19 , wherein the therapeutically effective amount of risperidone is an amount from about from 0.5 mg/day to about 17.5 mg/day.
21. The method according to claim 18 , wherein the therapeutically effective amount of risperidone is an amount from about 0.01 mg/kg/day to about 0.5 mg/kg/day.
22. The method according to claim 18 , wherein 9Z,11E conjugated Linoleic Acid is an amount from about from 0.5 mg/day to about 17.5 mg/day.
23. The method according to claim 18 , wherein 9Z,11E conjugated Linoleic Acid is an amount from about from 0.01 mg/kg/day to about 0.5 mg/kg/day.
24. The method according to claim 18 , wherein risperidone and 9Z,11E conjugated Linoleic Acid are administered sequentially or simultaneously.
25. The method according to claim 18 , wherein risperidone and 9Z,11E conjugated Linoleic Acid are administered to the individual as a single composition.
26. The method according to claim 10 , wherein risperidone is an amount from about 0.1 mg/day to about 20 mg/day.
27. The method according to claim 26 , wherein risperidone is an amount from about 0.5 mg/day to about 17.5 mg/day.
28. The method according to claim 10 , wherein 9Z,11E conjugated Linoleic Acid is an amount from about 0.1 mg/day to about 20 mg/day.
29. The method according to claim 28 , wherein 9Z,11E conjugated Linoleic Acid is an amount from about 0.5 mg/day to about 17.5 mg/day.